Allergan Shakes Shareholders' Off-Label Botox Case
A California federal judge Wednesday tossed a derivative shareholder suit accusing Allergan Inc.'s board members of improperly marketing the cosmetic drug Botox for off-label uses after a voluntary dismissal by the...To view the full article, register now.
Already a subscriber? Click here to view full article